Ri Xiang Kong
Directeur Technique/Scientifique/R&D chez Beijing Biostar Pharmaceuticals Co. Ltd.
Postes actifs de Ri Xiang Kong
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/03/2021 | - |
| Directeur Technique/Scientifique/R&D | 01/12/2018 | - |
Historique de carrière de Ri Xiang Kong
Formation de Ri Xiang Kong
| Tianjin University of Science & Technology | Graduate Degree |
Statistiques
Internationale
| Chine | 3 |
Opérationnelle
| Graduate Degree | 1 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Consumer Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
- Bourse
- Insiders
- Ri Xiang Kong
- Expérience
